+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 120Years
All Genders
ID06494540

Non-interventional Study to Assess Tremelimumab, Durvalumab, and Platinum Chemotherapy in Metastatic Non-squamous NSCLC with High-risk Genetic Markers

Led by AstraZeneca · Updated on 2026-09-28

600

Participants Needed

30

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are gathering real-world data from patients in Germany with non-squamous metastatic non-small cell lung cancer NSQ mNSCLC, including large cell neuroendocrine carcinoma when considered similar to NSCLC. The study focuses on patients beginning their first-line treatment with a combination of tremelimumab, durvalumab, and platinum-based chemotherapy TDC as approved. It aims to understand treatment effectiveness based on specific genetic mutations like KRAS, STK11, KEAP1, TP53, and markers such as TTF-1 and PD-L1 to help guide personalized treatment strategies for high-need patient subgroups. Participants are observed without receiving additional interventions beyond their planned standard treatment with TDC. The study collects data according to routine clinical practice during the patients treatment course. Biomarker testing including molecular sequencing and expression analyses is performed as per institutional standards to classify patient subgroups. During the study, participants survival and treatment responses are tracked for up to 24 months, with key outcomes including real-world overall survival rates at two years, progression-free survival, and safety through adverse event collection. Data are gathered at multiple time points up to two years to evaluate outcomes in the overall population and in subgroups defined by genetic mutations. Participants provide informed consent and must meet specific eligibility criteria to join.

CONDITIONS

Brief Title

NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations

Research Team

A

AstraZeneca Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here